5 Dumbest Things on...
Health Care: Drugs
Ventrus Biosciences Inc. (VTUS: NASDAQ)
$2.66 -0.10 | -3.62%
05/24/13 - 04:00 PM ET
329.85K / 120.90K
Vol / Avg. Vol:2.82 / 2.76
Open / Prev. Close:2.64 - 2.83
Today's Range:1.99 - 12.88
52 Wk Range:23.61%
Performance YTD:TheStreet Rating:
Portfolios with VTUS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
Latest VTUS Headlines from TheStreet
- Ventrus Biosciences Announces Poster Presentation On The Quality Of Compounded Topical Diltiazem Hydrochloride Formulations For Anal Fissure At The American Pharmacists Association Meeting 03.01.13 | 08:03 am
- 5 Stocks Ready to Break Out 02.22.13 | 12:02 pm
- Ventrus Biosciences To Present At The Leerink Swann Global Healthcare Conference 02.11.13 | 02:02 pm
- Ventrus Biosciences Announces Full Exercise Of Overallotment Option By Underwriters 02.07.13 | 09:02 am
- Ventrus Biosciences Announces $20 Million Financing 01.30.13 | 08:01 am
- Ventrus Biosciences Announces Proposed Public Offerings Of Common Stock And Series A Convertible Preferred Stock 01.29.13 | 04:01 pm
- Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations And Business Development 09.24.12 | 07:09 am
- 4 Stocks Under $10 Making Big Moves 09.05.12 | 03:09 pm
- Ventrus Biosciences To Present At Upcoming Investor Conferences In September 08.29.12 | 07:08 am
- Ventrus Biosciences Reports Second Quarter 2012 Financial Results 08.09.12 | 05:08 pm
Press Releases for VTUS
- Holzer Holzer & Fistel, LLC Announces Investigation Into Ventrus Biosciences, Inc. - Business Wire 02.12.13 | 10:02 am
- Rodman & Renshaw Acts As A Co-Manager To Ventrus Biosciences, Inc. Underwritten Registered Offering Of Common Stock - Business Wire 07.14.11 | 06:07 pm
Partner Headlines for VTUS
- UPDATE: Cantor Fitzgerald Lowers PT on Ventrus Biosciences on 4Q Earnings Report - Benzinga 03.19.13 | 09:03 am
- Garmin NAVIGATES Ahead of Expectations and 4 Equity Insights to Watch - Wall St. Cheat Sheet 06.26.12 | 11:06 am
- Ventrus Biosciences IMPLODES 58% and 4 Stocks with Horrible News Now - Wall St. Cheat Sheet 06.25.12 | 11:06 am
- Ventrus Biosciences Down Over 50% on After Announcing Iferanserin Phase 3 Results - Benzinga 06.25.12 | 09:06 am
- Morning Market Losers - Benzinga 06.25.12 | 09:06 am
- Healthcare Biz Recap: FDA PROBES Pfizer's New Drug, Ventrus Biosciences ABANDONS Treatment - Wall St. Cheat Sheet 06.25.12 | 07:06 am
- Wall St. Equity Downgrades to Evaluate Now - Wall St. Cheat Sheet 06.25.12 | 02:06 am
- UPDATE: Brean Murray Carret Initiates Coverage on Ventrus Biosciences - Benzinga 06.14.12 | 09:06 am
- REVEALED: New Stock Analyst Coverage to Evaluate - Wall St. Cheat Sheet 06.14.12 | 03:06 am
- Ventrus Biosciences Pops 20% on Positive Phase 3 Trial - Benzinga 05.14.12 | 01:05 pm
